Novo Nordisk (NVO) Stock Gains Momentum After European Regulators Back Oral Wegovy

Key Takeaways

Table of Contents

European Medicines Agency (EMA) experts have endorsed Novo Nordisk’s pill-based Wegovy formulation for weight management
The drug becomes Europe’s inaugural oral obesity medication to secure regulatory committee backing
Clinical data revealed participants achieved 16.6% average weight reduction compared to placebo’s 2.7%
Final authorization awaits European Commission approval before commercial launch
US market entry occurred earlier this year for Novo’s pill; competitor Eli Lilly released Foundayo in April

European drug regulators have backed Novo Nordisk’s tablet version of Wegovy, setting the stage for it to become Europe’s pioneering approved oral obesity treatment.

Novo Nordisk A/S, NVO

The positive opinion arrived from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on Friday, May 22. This represents an expansion of Wegovy’s current European license, which presently encompasses only the weekly injection formulation.

The European Commission will evaluate the CHMP’s endorsement before rendering a conclusive verdict on commercial authorization.

NVO stock stood near $65 in New York trading when the news broke, although shares have experienced headwinds this year from general market turbulence and competitive pressures.

The tablet features semaglutide — identical to the active compound in Novo’s injected Wegovy and Ozempic formulations. The pharmaceutical giant previously introduced an oral semaglutide medication for type 2 diabetes marketed as Rybelsus.

The EMA’s endorsement stems from results of advanced-phase clinical research. Participants receiving the 25mg oral Wegovy experienced average body weight reductions of 16.6% across 64 weeks. Those on placebo shed merely 2.7%.

According to the EMA, the tablet “provides an oral option to weekly subcutaneous injections that could prove more practical for certain patients.” The medication is intended for use with dietary modifications and exercise in obese or overweight adults presenting at least one weight-associated health condition.

Competition Between Novo and Lilly in Oral Formulations

Novo secured first-mover status in America. The pharmaceutical company introduced its Wegovy tablet domestically following FDA clearance in December 2024, ahead of Eli Lilly’s daily weight-loss pill Foundayo which debuted stateside in April 2026.

Across the Atlantic, Novo again claims the early positioning benefit. Lilly’s oral obesity treatment has yet to receive EMA committee support.

Initial American prescription figures for both medications have been robust, reinforcing the notion that pill alternatives broaden the total addressable market instead of merely shifting patients from injectable products.

Industry analysts project the obesity pharmaceutical sector will reach $150 billion in annual revenue over the coming decade. Both Novo and Lilly are competing aggressively to establish dominance through oral treatment alternatives.

Looking Ahead

The CHMP’s recommendation advances to the European Commission, which will deliver the official marketing authorization ruling. This procedure should conclude during summer months, based on comments from EMA head Emer Cooke to Reuters last month.

Following Commission approval, the oral Wegovy tablet will become available for medical prescription throughout EU nations. Novo possesses established distribution networks from its existing injectable Wegovy deployment across Europe.

The oral Wegovy formulation requires daily administration. The EMA’s backing covers the 25mg strength evaluated in the key clinical study.

✨ Limited Time Offer